Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jinghua Weikang Capsule for prevention and treatment of antiplatelet drug-induced gastric and small intestinal mucosal injury
ChiCTR2000029964Phase 4Recruiting
- Sponsor
- China-Japan Union Hospital of Jilin University
- Start
- Jan 2016
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of jinghuaweikang and teprenone in gastrointestinal mucosal injury (4 arms), sponsored by China-Japan Union Hospital of Jilin University. Primary endpoint: Capsule endoscopy score. Started Jan 2016; status: recruiting.
02
Drugs
jinghuaweikangteprenone
03
Conditions
gastrointestinal mucosal injury
Beyond the preview
Go deeper on ChiCTR2000029964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029964.